Offerings Now Encompass Multiplex and Parallel Analysis of Cells, Proteins, and Genes Affymetrix, best known for its pioneering work in commercializing microarrays for gene expression research since ...
Like it or not, biologists have to deal increasingly in informatics as their experiments generate ever larger and more complex data sets. Few laboratories have the resources to develop their own ...
Genomatix Software GmbH today announced that it has achieved GeneChip-compatible TM status for several products with the Affymetrix Inc. (Nasdaq: AFFX) GeneChip® microarray platform and that it has ...
Affymetrix Inc. has announced the publication of the MicroArray Quality Control (MAQC) study, a collaborative effort led by the FDA that included 137 scientists from private and public sector ...
Ingenuity Systems and Affymetrix will be co-promoting Ingenuity® iReport™ with Affymetrix’ expression microarray products to help eliminate a bottleneck for researchers working with human, mouse, and ...
Unique and optimized solution provides highly sensitive and reproducible RNA amplification and labeling from archived FFPE samples for biomarker discovery and validation on industry-leading ...
Collaboration to expand research and molecular breeding tools for enhancing plant, crop, and livestock production outcomes SANTA CLARA, Calif.--(BUSINESS WIRE)-- Affymetrix, Inc. (NASDAQ:AFFX), ...
The DNA marketplace is changing: the technology is maturing, whole human genome arrays, as well as those of model organisms, are beginning to make it onto the market, and researchers have more choices ...
The concordance of RNA-sequencing (RNA-seq) with microarrays for genome-wide analysis of differential gene expression has not been rigorously assessed using a range of chemical treatment conditions.
SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq:AFFX) announced today that it has entered into a definitive agreement to acquire Panomics Inc., a privately held Fremont, Calif.-based ...
TEL AVIV (MarketWatch) -- Affymetrix Inc., the Santa Clara, Calif., developer of products based on genetic microarray technology, named Kevin M. King chief executive and a director, effective Jan. 1.
Mindy Lee-Olsen, 408-731-5523 (Media)Vice President, Marketing ServicesorDoug Farrell, 408-731-5285 (Investors)Vice President, Investor Relations (NASDAQ:AFFX) announced today the availability of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results